May 11 (Reuters) - Denmark's Bavarian Nordic BAVA.CO on Monday raised its revenue guidance for 2026 to 5.5 billion - 5.7 billion Danish crowns ($866.93 million-$898.46 million).

The vaccine maker also said it has been awarded contract options valued at $97 million from the U.S. Department of Health and Human Services to supply a freeze-dried formulation of the JYNNEOS smallpox vaccine.

($1 = 6.3442 Danish crowns)